Business
Align Research Initiation of Coverage
Align Research Initiation of Coverage.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 3152G Hemogenyx Pharmaceuticals PLC 01 March 2018 \n\n \nHemogenyx Pharmaceuticals Plc\n(\"Hemogenyx\" or the \"Company\")\n \nAlign Research Initiation of Coverage\n \n \nHemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that Align Research (\"Align\")has today initiated research coverage on the Company. The Company is pleased to note the comments of Align in their research note (\"Note\") including its \"conviction buy\" stance and target price of 18.15 pence. However, the Board wishes to emphasize that the views expressed in the Note are those of Align alone.\n \nThe Note should be read in full. To download it visit: \nhttp://www.alignresearch.co.uk/cpt-company/hemogenyx-pharmaceuticals/ or www.hemogenyx.com/research/\n \nAs always shareholders should speak to their own financial adviser before entering into any dealings in the Company's shares. In particular, whilst the Company confirms the views attributed to it in the Note on recent trading, there is no certainty that the possible future collaborations and the Board's great confidence can be realized in full or within the Company's current development timetable. The views expressed by Align on the Company's valuation and prospects are a matter of opinion and the Company is in no position to comment on whether they are accurate.\n \nThe Company also wishes to draw attention to the key risks identified by Align and its disclaimer and risk warning and the qualifications that it makes in its conclusion to the Note. Shareholders should also note that the Company is a research client of Align and that Align holds shares in the Company\n \nEnquiries:\n \n\n\n\n\nHemogenyx Pharmaceuticals Limited\n\n\nwww.hemogenyx.com\n\n\n\n\nDr Vladislav Sandler, Chief Executive Officer & Co-Founder\n\n\nVia Walbrook PR\n\n\n\n\nDr Robin Campbell, Chairman\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nOptiva Securities Ltd\n\n\nTel: +44 (0)20 3137 1902\n\n\n\n\nChristian Dennis \n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nShard Capital Partners LLP\n\n\nTel: +44 (0)20 7186 9950\n\n\n\n\nDamon Heath, Erik Woolgar\n\n\n \n\n\n\n\n \n\n\n \n...